Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ARCT
SILVERARC CAPITAL MANAGEMENT, LLC position in ARCT
ARCTURUS THERAPEUTICS HLDGS · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 459,899 shares of ARCT (ARCTURUS THERAPEUTICS HLDGS) in its Q3 2026 13F filing — a position valued at US$6.3M, representing 0.80% of its reported portfolio and ranking #33 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ARCT holdings in 2 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's ARCT position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ARCT in Q3 2025 at 3,445 shares (US$63K). The position peaked in Q3 2026 at 459,899 shares, worth US$6.3M. Across 2 filings, SILVERARC CAPITAL MANAGEMENT, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 459,899 shares valued at US$6.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 3.44K | $63.49K | New |
| Q3 2026 | 459.90K | $6.30M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARCT and 13F data
ARCT (ARCTURUS THERAPEUTICS HLDGS) is a Health Care company. 20 other funds we track also report a position in ARCT. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held ARCT?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ARCT holdings in 2 of the last 5 reported quarters, going back to Q3 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ARCT?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 459.90K shares of ARCT (ARCTURUS THERAPEUTICS HLDGS), valued at $6.30M, representing 0.80% of its reported portfolio and ranking #33.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ARCT?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC newly opened its position in ARCT. The position peaked in Q3 2026 at 459.90K shares.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.